B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
Influence of rapidly oscillating inspired O2 and N2 concentrations on pulmonary vascular function and lung fluid balance in healthy adults
TL;DR: In this paper , the authors used a rebreathe method for quantifying pulmonary blood flow (Qc), pulmonary capillary blood volume (Vc), and alveolar-capillary conductance (Dm), and found that exposure to the 120 s oscillations resulted in a significant decrease in Vc at the recovery testing period and an increase in the Dm/Vc ratio at both the post and recovery period.
Journal ArticleDOI
Associations between biomarker testing and characteristics of patients with metastatic non–small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data.
Kathryn Finch Mileham,Elizabeth Garrett-Mayer,Melinda Kaltenbaugh,M. K. Kirkwood,Caroline Schenkel,Suanna S. Bruinooge,Raymond U. Osarogiagbon,Shadia I. Jalal,Amy P. Moore,Upal Basu Roy,Janet Freeman-Daily,Shamsuddin Virani,Edward B. Garon,Gerard A. Silvestri,Lauren S. Rosenthal,Robert A. Smith,Bruce E. Johnson +16 more
TL;DR: Investigating the association between the presence of biomarker testing and smoking status, age, sex, race, ethnicity, histology, and diagnosis year in patients with mNSCLC demonstrated annual increases in testing rates, reflecting guideline changes.
Journal ArticleDOI
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
Gregory J. Riely,Egbert F. Smit,Myung-Ju Ahn,Enriqueta Felip,Suresh S. Ramalingam,Anne Tsao,Melissa Lynne Johnson,Francesco Gelsomino,Ernest Nadal,Michael Offin,Mariano Provencio,Jeffrey M. Clarke,Gregory A. Otterson,Ibiayi Dagogo-Jack,Jonathan W. Goldman,Daniel Morgensztern,Ann Alcasid,Tiziana Usari,Paul Wissel,Keith D. Wilner,Nuzhat Pathan,Bruce E. Johnson +21 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic nonsmall-cell lung cancer (NSCLC).
Meta- analysis of EGF r Kinase inhibitors: Not a lways Greater t han the Sum of i ts Parts
TL;DR: The results of the meta-analysis once again confirm the consistent superiority of EGFR TKIs in prolonging the PFS of patients with advanced NSCLC bearing EGFR mutations compared with wild-type EGFR, with hazard ratios (HRs) of 0.43 (95% confidence interval [CI] = 0.38 to 0.49).